Acute Myeloid Leukemia Refractory research hub
4 indexed studies · 4 currently recruiting
- recruitingPHASE1
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
This study is testing a new drug, APL-4098, alone and with other medicines, for adults with certain types of blood cancers like Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). Doctors want to see if it's safe, how well it's tolerated, and if it helps.
Australia · United Kingdom - recruitingPHASE1
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
This study is testing a new treatment called Allo-RevCAR01-T-CD123 for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML) that has come back or isn't responding to other treatments. It’s a very early-stage trial (Phase 1) to check if the treatment is safe.
Germany · Netherlands - not yet recruitingPHASE1, PHASE2
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
This study is testing a new drug called CCTx-001 for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML) that has come back or not responded to previous treatments. It aims to see if CCTx-001 is safe, well-tolerated, and effective.
France · Germany · Spain - recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
This study looks at how people with acute myeloid leukaemia (AML) respond to treatment when their cancer comes back or doesn't respond well to initial therapy. It collects important real-world information to help improve care for patients across Europe.
Germany · Italy · Lithuania